Partnerships Barinthus Biotherapeutics (IM-PROVE II collaboration, completed; Phase 2b not pursued); Qilu Pharmaceutical (license terminated June 2025, global rights returned to Arbutus)
Indications
chronic hepatitis B (cHBV)(Phase 2)
Status note Two Phase 2a trials (IM-PROVE I, IM-PROVE II) completed; Qilu partnership terminated with global rights returned to Arbutus; Phase 2b combination with VTP-300 not pursued after Barinthus postponed VTP-300 development; discovery operations ceased but clinical program active.
Status note Phase 1 trial in healthy subjects; FDA clinical hold on IND; no discontinuation disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.